<DOC>
	<DOCNO>NCT02294643</DOCNO>
	<brief_summary>The purpose SERENADE trial evaluate safety efficacy sarpogrelate patient CKD DM DES implantation .</brief_summary>
	<brief_title>Study Design 'Influence Sarpogrelate Patients With Renal Impairment Diabetes Mellitus ' Study</brief_title>
	<detailed_description>The rate stent failure percutaneous intervention ( PCI ) decline introduction drug elute stent ( DES ) . However , chronic kidney disease ( CKD ) diabetes mellitus ( DM ) still remain strong clinical predictor poor prognosis DES . Sarpogrelate , selective 5-HT2a receptor antagonist , antiproliferative effect show reduction neointimal hyperplasia smooth muscle cell proliferation well potent antiplatelet agent inhibit 5-HT-induced platelet aggregation . However , efficacy safety data sarpogrelate patient CKD DM limit . We aim test whether sarpogrelate beneficial effect patient CDK DM treat DES . The SERENADE trial multicenter , off-label , prospective , placebo-controlled randomize study test superiority triple anti-platelet therapy ( TAT ; aspirin , clopidogrel sarpogrelate ) conventional dual antiplatelet therapy ( DAT ; aspirin clopidogrel ) prevent late lumen loss 9 month index procedure patient CKD DM . A total 220 patient exhibit coronary artery disease ( CAD ) DM CKD randomize TAT DAT ( 1:1 ratio ) DES implantation . Primary endpoint late lumen loss 9 month assess quantitative coronary angiography ( QCA ) . Secondary efficacy endpoint composites major adverse cardiovascular event ( MACE ) include cardiac death , nonfatal myocardial infarction ( MI ) , target lesion revascularization . Secondary safety endpoint major bleed event hepatic renal impairment . The SERENADE trial give insight whether adjunctive therapy sarpogrelate helpful patient high risk profile CKD DM DES implantation .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Sarpogrelate</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>symptomatic CAD ( include acute coronary syndrome ) positive stress test native coronary lesion ( &gt; 50 % diameter stenosis visual estimation coronary angiogram reference diameter &gt; 2.5 mm ) AND CKD DM patient contraindication aspirin , clopidogrel sarpogrelate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>sarpogrelate</keyword>
</DOC>